iPSC-Based Manufacture vs. Autologous Model Production Costs Examined via Financial Analysis
Decoupling production from the patient and stem cell donors via a universal master cell bank lets NK cell therapy manufacturers slash COGS, simplify logistics, and reduce patient attrition. The post iPSC-Based Manufacture vs. Autologous Model Production Costs Examined via Financial Analysis appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Source
Read the full article at Genengnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.